Europe PMC

The DESolve novolimus bioresorbable Scaffold: from bench to bedside.

The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold ...
FiercePharma

Elixir Medical Announces First Commercial Implant Of The DESolve® Novolimus Eluting Coronary Scaffold System in Europe

SUNNYVALE, Calif.--(BUSINESS WIRE)--Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's ...
hospitalhealthcare

Bioresorbable DESolve device

The DESolve Nx trial treated target lesions in 126 patients with single de novo coronary artery lesions with the DESolve device. Results showed the primary endpoint of in-stent late lumen loss was ...
Europe PMC

An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition).

The strut thickness and crossing profile of the polymeric scaffolds was greater than those of the metallic drug-eluting stent. While all three devices recoiled after deployment, the DESolve enlarged ...
BioSpace

Elixir Medical’s DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System CE Marked

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has ...
FiercePharma

Successful Live Case Demonstration of Elixir Medical's CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that the successful ...
TCTMD

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

A matched comparison of two disappearing stents, one of which dissolves as early as 1 to 2 years after implantation, suggests the two platforms perform equally well and result in similar clinical ...
GitHub

desolve failed to solve an ODE whose solution implies integration limits #11653

This comment has been minimized. Sign in to view sagetrac-JGuzman mannequin assigned sagetrac-JGuzman and unassigned burcin Aug 7, 2011 sagetrac-JGuzman mannequin changed the title desolve failed to ...
Business Wire

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve ® 100 Novolimus Eluting Coronary Scaffold System

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has ...
TCTMD

Angiographic Results of the DESolve Nx Clinical Trial with the Novel DESolve Nx Novolimus-eluting Bioresorbable Coronary Scaffold System

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Healio

DESolve Nx: 6-month results strong for bioresorbable scaffold

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARIS — The DESolve NX pivotal trial has indicated ...
GitHub

Fits using solution_type = "deSolve" give incorrect results if no oberserved data are available for time zero #16

jranke commented Feb 16, 2025 This became obvious when comparing results obtained five years ago using the SFO-SFO model with "deSolve", because the solution method "analytical" was not implemented ...